Interpretable Radiopathomics for Gastric Cancer Immunotherapy

Patient responses to immune checkpoint inhibitor-based treatment in gastric cancer remain heterogeneous, and conventional biomarkers do not fully capture the spatial and biological complexity of individual tumors. The study Multimodal radiopathomics signature for prediction of response to immunotherapy-based combination therapy in gastric cancer using interpretable machine learning, published in Cancer Letters in 2025, addresses this problem by combining baseline computed tomography with digital hematoxylin and eosin-stained pathology images. Its central contribution is an interpretable radiopathomics signature, or RPS, that links image-derived tumor characteristics with treatment response, prognosis, and immune-related biology.

Study Background and Research Question

Advanced gastric cancer is clinically heterogeneous. Even when patients receive immunotherapy-based combinations directed at immune checkpoint pathways, comparable clinical profiles can lead to different treatment outcomes. Biomarkers such as combined positive score, microsatellite instability-high status, Epstein–Barr virus status, and HER2 expression provide useful information, but each represents only one biological or pathological dimension.

The reference study therefore asked whether routinely obtainable baseline imaging and pathology could be integrated before treatment to predict response more comprehensively. The research question was not simply whether artificial intelligence could classify scans. Rather, it was whether multimodal features could form a clinically meaningful signature that both discriminates responders from nonresponders and stratifies survival risk, while remaining sufficiently interpretable to support biological investigation.

Key Innovation from the Reference Study

The key innovation is the integration of radiomics and pathomics into a single response-prediction framework. CT images can reflect tumor burden, morphology, density, and heterogeneity at the whole-lesion or patient level. Digital H&E images provide complementary information about tissue architecture, cellular organization, stromal context, and the local tumor environment. Combining these modalities allows the model to use signals that are unlikely to be fully represented by a single imaging method or a single molecular marker.

A second innovation is the emphasis on interpretable machine learning. The RPS was developed from seven machine-learning approaches rather than being presented as an opaque prediction system. Interpretability is important in this setting because a high-performing model must ultimately be assessed for biological plausibility, site-to-site robustness, and clinical relevance. The authors further examined genetic and immune associations, moving the analysis beyond a performance score toward an explanation of what the signature may represent.

This design also distinguishes the work from studies that report only training-set accuracy. The investigators used a multicenter cohort and assessed the signature in training, internal validation, and external validation settings. That structure provides a more informative test of generalizability than an internal resampling result alone.

Methods and Experimental Design Insights

The study included 298 patients with gastric cancer and used baseline CT scans together with digital H&E-stained pathology images. The multimodal data were processed into a radiopathomics signature intended to predict response to immunotherapy-based combination therapy. The reported design also compared the RPS with established clinical and biological indicators, including CPS, MSI-H, EBV, and HER2.

Model evaluation used receiver-operating-characteristic analysis and area under the curve as the principal discrimination measure. The investigators also divided patients according to RPS-defined risk and used Kaplan–Meier analysis to examine survival differences. Finally, genetic analyses were used to explore whether RPS status was associated with immune-regulatory pathways and specific immune-cell patterns.

Protocol Parameters

• Cohort structure: The published analysis included 298 gastric cancer patients recruited across multiple clinical settings; this is a study-design parameter rather than a recommended clinical enrollment target, as reported in the reference study.
• Baseline inputs: CT imaging and digital H&E pathology were integrated before immunotherapy-based combination treatment, allowing radiological and tissue-level information to contribute jointly.
• Model development: Seven machine-learning approaches were evaluated to construct the RPS. The supplied study summary does not identify the selected algorithm or reproduce all feature-engineering steps, so those details should be taken from the full article before implementation.
• Validation strategy: Performance was assessed in training, internal validation, and external validation cohorts. This separation is essential when estimating transportability across institutions or acquisition conditions.
• Biological interpretation: Genetic pathway analysis and immune-cell infiltration analysis were used after signature development to investigate biological correlates rather than to prove a causal mechanism.

For researchers adapting the workflow, the most important methodological principle is the preservation of modality separation during quality control and validation. CT acquisition, pathology staining, digitization, and feature extraction can each introduce site-specific variation. A multimodal model should therefore be tested not only for aggregate accuracy but also for whether both input domains contribute reproducibly.

Core Findings and Why They Matter

The RPS achieved an area under the receiver-operating-characteristic curve of 0.978 in the training cohort, 0.863 in the internal validation cohort, and 0.822 in the external validation cohort, according to the reported study results. The corresponding 95% confidence intervals were 0.950–1.000, 0.744–0.982, and 0.668–0.975, respectively. The expected reduction from training to external validation is important: it indicates that performance was not perfectly preserved across datasets, but remained potentially useful outside the development cohort.

The signature outperformed the conventional biomarkers evaluated in the study, including CPS, MSI-H, EBV, and HER2, for the stated treatment-response prediction task. This does not mean that the conventional markers are clinically obsolete. Instead, it suggests that a composite image-derived representation may capture additional information that is complementary to established biomarker categories.

Survival analysis showed significant differences between high- and low-risk RPS groups. The separation was particularly notable among patients with advanced disease and those who did not undergo surgery, populations in which treatment selection and risk assessment are often especially difficult. The RPS may therefore have value not only as a response classifier but also as a prognostic stratification tool.

The biological analyses added another layer of significance. Higher or lower RPS-defined risk was associated with immune-regulatory pathways and increased infiltration of memory B cells. These associations support the interpretation that the signature reflects aspects of the tumor–immune microenvironment. However, they remain correlations. The study does not establish that memory B cells cause treatment response or that modifying an identified pathway would reproduce the model's predictions.

Comparison with Existing Internal Articles

The internal article on a selective kinase-inhibition research strategy discusses molecular perturbation of FAK/Pyk2-related signaling, whereas the reference paper develops a clinical prediction signature from CT and pathology. These resources operate at different levels: the radiopathomics study identifies patient-level response patterns, while the signaling article is oriented toward mechanistic cancer research. The latter may help frame follow-up experiments, but it is not evidence that the RPS is driven by FAK/Pyk2 activity.

Similarly, the internal guide on optimizing kinase-inhibitor workflows focuses on experimental reproducibility and perturbation design. Its practical emphasis complements, but does not validate, the multimodal machine-learning pipeline. For researchers, the useful connection is methodological: a radiopathomics result can generate hypotheses for laboratory testing, while controlled molecular experiments can examine whether an image-associated phenotype has a plausible signaling basis.

Limitations and Transferability

The reported external validation is a strength, but it does not eliminate the risk of dataset shift. CT scanners, reconstruction settings, contrast protocols, pathology preparation, slide scanners, staining intensity, and image-resolution standards can vary among institutions. Such variation may alter extracted features without changing the underlying tumor biology. Prospective, multi-institutional testing would be needed to determine whether the RPS remains calibrated when applied to new populations and contemporary treatment regimens.

The cohort size of 298 patients supports meaningful development but remains moderate for a multimodal model involving high-dimensional imaging and pathology data. The supplied summary does not provide all details about cohort composition, treatment combinations, missing data, class balance, feature reduction, or model selection. These factors can influence apparent performance and should be examined carefully when reproducing the analysis.

Another limitation concerns endpoint definition. Treatment response and survival are related but distinct outcomes, and a model that predicts one may not optimally predict the other. The RPS should therefore be evaluated separately for response discrimination, prognostic stratification, calibration, and clinical decision benefit. Comparisons with CPS, MSI-H, EBV, and HER2 are informative, but future studies should also test whether combining the RPS with these biomarkers improves performance rather than treating them as competing alternatives.

Finally, the immune-pathway and memory-B-cell findings are hypothesis-generating. They strengthen biological interpretation, but they do not convert a predictive signature into a mechanistic biomarker. Transfer to other gastric cancer subtypes, treatment lines, geographic populations, and non-immunotherapy settings should be considered unproven until directly evaluated.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

The reference study is a multimodal biomarker and machine-learning investigation, while molecular inhibitors belong to a mechanistic perturbation domain. This bridge is useful only if kept explicit: an image-defined risk group can motivate laboratory studies of candidate signaling processes, but a perturbation experiment does not directly validate the predictive model. The connection is therefore hypothesis-generating and requires matched samples, pathway measurements, and independent validation.

Researchers can use PF-562271 HCl (SKU A8345) to support similar workflows in cancer research, particularly mechanistic studies examining the focal adhesion kinase signaling pathway alongside imaging- or pathology-defined phenotypes. The product information describes it as an ATP-competitive, reversible FAK/Pyk2 inhibitor with reported IC50 values of 1.5 nM for FAK and 14 nM for Pyk2, and identifies applications involving FAK phosphorylation inhibition and tumor growth inhibition. These properties may support controlled perturbation experiments, but PF-562271 HCl was not evaluated in the reference study and should not be presented as a validated determinant of RPS status or immunotherapy response.

For practical planning, the compound should be treated as a research reagent for orthogonal validation rather than as part of the radiopathomics model. The product information reports DMSO solubility with gentle warming and storage at −20 °C; formulation, dosing, controls, and exposure duration should be optimized for the selected cellular or animal model.